<DOC>
	<DOCNO>NCT02062645</DOCNO>
	<brief_summary>The population include study , regular Turkish hypertensive patient expect consume sodium high amount . It hypothesize , population , amlodipine/valsartan effective rate blood pressure ( BP ) control rate expect literature .</brief_summary>
	<brief_title>Study Efficacy Safety CVAA489 Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female , 18 year age Diagnosis essential hypertension Newly diagnose , Previously untreated , Currently untreated ( regular antihypertensive treatment previous least 1month period ) Written informed consent Known suspect secondary hypertension eGFR low 30 mL/min Use hypertension treatment enrollment need use relate treatment study phase History hypersensitivity study drug drug similar chemical class . ( i.e . valsartan , amlodipine , hydrochlorothiazide ) History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Use investigational drug within 5 halflives enrollment , within 30 day expect PD effect return baseline , whichever longer.Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>essential hypertension</keyword>
</DOC>